RRC ID 70408
Author Han Y, Dong Q, Liu T, Chen X, Yu C, Zhang Y.
Title The novel mechanism of Med12-mediated drug resistance in a TGFBR2-independent manner.
Journal Biochem Biophys Res Commun
Abstract Inevitable emergence of drug resistance is the biggest hurdle to both chemotherapies and targeted therapies. Understanding the resistance mechanisms will contribute to identification of biomarkers for predicting response to therapy and design new therapeutic strategies to overcome drug resistance in human cancers. The type II transforming growth factor (TGF)-β receptor gene (TGFBR2) is frequently frameshift mutated in several cancer types, especially in colorectal, endometrium and gastric cancers cells. Here, we found that Med12, a component of the transcriptional mediator complex, plays a role in modulating chemosensitivity in TGFBR2 deficient cancer cells. Loss of Med12 leads to chemoresistance in multiple TGFBR2 deficient cancer cells. Interestingly, RNA sequencing data revealed that interferon IFN-related DNA damage resistance signature (IRDS) is upregulated in Med12 knockdown cancer cells. And the expression of IRDS pattern is negatively correlated with chemosensitivity. Therefore, our study identifies a novel mechanism of Med12-mediated drug resistance, which is a TGFBR-independent manner.
Volume 610
Pages 1-7
Published 2022-6-25
DOI 10.1016/j.bbrc.2022.04.029
PII S0006-291X(22)00552-6
PMID 35461070
MeSH Drug Resistance, Neoplasm Humans Mediator Complex* / genetics Mediator Complex* / metabolism Neoplasms* / drug therapy Neoplasms* / genetics Receptor, Transforming Growth Factor-beta Type II* / genetics Receptor, Transforming Growth Factor-beta Type II* / metabolism
IF 2.985
Resource
Human and Animal Cells TGBC11TKB(RCB1148) MKN1(RCB1003) MKN45(RCB1001) GSU(RCB2278) GCIY(RCB0555)